MAPT and Alzheimer disease: Its preceding mouse version (antibody D) reportedly inhibited transneuronal propagation of pathogenic and aggregated tau in vivo (Albert et al., 2019), and seeding activity of human AD and PSP tau in vitro (Courade et al., 2018).